Tags

Type your tag names separated by a space and hit enter

Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
Expert Opin Pharmacother. 2005 Oct; 6(12):2141-4.EO

Authors+Show Affiliations

Division of Health Practice, Auckland University of Technology - Akoranga Campus, Northcote, Auckland, New Zealand. s.doggrell@xtra.co.nz

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16197364

Citation

Doggrell, Sheila A.. "Is the Cannabinoid CB1 Receptor Antagonist Rimonabant Advancing the Treatment of Obesity?" Expert Opinion On Pharmacotherapy, vol. 6, no. 12, 2005, pp. 2141-4.
Doggrell SA. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity? Expert Opin Pharmacother. 2005;6(12):2141-4.
Doggrell, S. A. (2005). Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity? Expert Opinion On Pharmacotherapy, 6(12), 2141-4.
Doggrell SA. Is the Cannabinoid CB1 Receptor Antagonist Rimonabant Advancing the Treatment of Obesity. Expert Opin Pharmacother. 2005;6(12):2141-4. PubMed PMID: 16197364.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity? A1 - Doggrell,Sheila A, PY - 2005/10/4/pubmed PY - 2006/6/2/medline PY - 2005/10/4/entrez SP - 2141 EP - 4 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 6 IS - 12 SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/16197364/Is_the_cannabinoid_CB1_receptor_antagonist_rimonabant_advancing_the_treatment_of_obesity L2 - https://www.tandfonline.com/doi/full/10.1517/14656566.6.12.2141 DB - PRIME DP - Unbound Medicine ER -